Metabotropic Glutamate Receptor Genes as Candidates for Pharmacogenetic Studies of Current and Future Antipsychotic Agents in Schizophrenia

Authors: Bishop, Jeffrey R.¹; Ellingrod, Vicki L.¹

Source: Current Pharmacogenomics, Volume 5, Number 1, March 2007 , pp. 21-30(10)

Publisher: Bentham Science Publishers

Purchase options

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$55.10 plus tax Refund Policy

More about this publication?

Current Pharmacogenomics provides comprehensive overviews of all current research on pharmacogenomics and pharmacogenetics. All areas of the field from pre-clinical to clinical research are covered, including related areas such as genomics, proteomics, target discovery, bioinformatics and novel diagnostics. This international journal is peer-reviewed and publishes both mini- and full review articles.

The journal has become essential reading for all researchers and clinicians with interests in pharmacogenomics and pharmacogenetics.

More like this?

In this: publication
By this: publisher
In this Subject: Pharmacology , Genetics
By this author: Bishop, Jeffrey R. ; Ellingrod, Vicki L.

Content Key:

- Free

- New

- Open Access

- Subscribed

- Free Trial

Abstract:

Recent research has linked the polymorphic metabotropic glutamate receptors to the pathogenesis of schizophrenia contributing to the development of the “glutamate hypothesis”. These receptors regulate glutamate through NMDA inotropic receptors. At the neurotransmitter level, antipsychotics developed to treat schizophrenia have been found to significantly increase serum glutamate levels and potentially affect the expression of various metabotropic glutamate receptors (mGluRs). Additionally, type-3 metabotropic glutamate receptor gene (GRM3) polymorphisms have been associated with schizophrenia as well as being linked to reductions in prefrontal cortex N-acetylaspartate concentrations. Thus, glutamate has become an increasingly important area of interest for therapeutic intervention in schizophrenia and pharmaceutical companies are rapidly focusing on the development of agents that directly modulate this neurotransmitter; however the reality is that the clinical use of such drugs is still years away. Taken together, investigations of how genetic variability in genes coding for mGluRs relate to treatment outcomes are becoming increasingly important. The goal of this review is to discuss the genetics, pharmacology, and pharmacogenetics of the metabotropic glutamate receptors focusing on receptor subtypes with the most evidence for involvement with current and/or future antipsychotic activity.

Keywords: NMDA receptors; Group I mGluRs; Single Nucleotide Polymorphisms; dopamine; Prefrontal Cortex

Document Type: Research article

DOI: 10.2174/157016007780077220

Affiliations: 1: The University of Michigan,College of Pharmacy and Medicine, Departments of Clinical Science & Psychiatry, 428 Church Street, Ann Arbor, MI 48109, USA.